TerminatedPhase 4

Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.

Stopped: The study was terminated early due to a shortage of research and analytical personnel, which prevented the completion of the study as planned

South Korea150 participantsStarted 2009-08

Plain-language summary

Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * non-ST segment elevation acute myocardial infarction * within 48 hours presence of chest pain * Troponin-T or I positive before CAG * First myocardial infarction * will be performed coronary angioplasty Exclusion Criteria: * under 18 years of age,80 years or older * Bleeding tendency * History of major surgery within 4 weeks * Major stroke within 2 years * Thrombocytopenia (\<120,000 / uL) * Cardiogenic shock * Known allergy to aspirin, heparin, or abciximab * Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc) * Chronic atrial fibrillation * Pregnancy

What they're measuring

In cardiac MRI- infarct size (total late enhancement volume at day 3-7)

Timeframe: day 3~7 after percutaneous coronary intervention

Trial details

NCT IDNCT01080638

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Myocardial Infarction trials